JP2023554467A - Ｇｕｃｙ２ｃ結合分子及びその使用 - Google Patents

Ｇｕｃｙ２ｃ結合分子及びその使用 Download PDF

Info

Publication number
JP2023554467A
JP2023554467A JP2023537253A JP2023537253A JP2023554467A JP 2023554467 A JP2023554467 A JP 2023554467A JP 2023537253 A JP2023537253 A JP 2023537253A JP 2023537253 A JP2023537253 A JP 2023537253A JP 2023554467 A JP2023554467 A JP 2023554467A
Authority
JP
Japan
Prior art keywords
seq
amino acid
acid sequence
gucy2c
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023537253A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023554467A5 (https=
Inventor
ヘ リン
ワン リン
ワン ウェイ
Original Assignee
パラソル バイオテック エルティーディー．
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by パラソル バイオテック エルティーディー． filed Critical パラソル バイオテック エルティーディー．
Publication of JP2023554467A publication Critical patent/JP2023554467A/ja
Publication of JP2023554467A5 publication Critical patent/JP2023554467A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001154—Enzymes
    • A61K39/001164—GTPases, e.g. Ras or Rho
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4244—Enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4244—Enzymes
    • A61K40/4253—GTPases, e.g. Ras or Rho
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70517—CD8
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/50—Colon
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y406/00—Phosphorus-oxygen lyases (4.6)
    • C12Y406/01—Phosphorus-oxygen lyases (4.6.1)
    • C12Y406/01002—Guanylate cyclase (4.6.1.2)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
JP2023537253A 2020-12-17 2021-12-16 Ｇｕｃｙ２ｃ結合分子及びその使用 Pending JP2023554467A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CNPCT/CN2020/137164 2020-12-17
CN2020137164 2020-12-17
PCT/CN2021/138845 WO2022127871A1 (en) 2020-12-17 2021-12-16 Gucy2c binding molecules and uses thereof

Publications (2)

Publication Number Publication Date
JP2023554467A true JP2023554467A (ja) 2023-12-27
JP2023554467A5 JP2023554467A5 (https=) 2025-01-08

Family

ID=82060074

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023537253A Pending JP2023554467A (ja) 2020-12-17 2021-12-16 Ｇｕｃｙ２ｃ結合分子及びその使用

Country Status (15)

Country Link
US (1) US20240059794A1 (https=)
EP (1) EP4263615A4 (https=)
JP (1) JP2023554467A (https=)
KR (1) KR20230131183A (https=)
CN (2) CN118146381A (https=)
AU (1) AU2021404641A1 (https=)
BR (1) BR112023011658A2 (https=)
CA (1) CA3205007A1 (https=)
CL (1) CL2023001665A1 (https=)
CO (1) CO2023009279A2 (https=)
CR (1) CR20230245A (https=)
EC (1) ECSP23053774A (https=)
IL (1) IL303610A (https=)
MX (1) MX2023006969A (https=)
WO (1) WO2022127871A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202413437A (zh) * 2022-08-05 2024-04-01 大陸商江蘇恆瑞醫藥股份有限公司 特異性結合ｇｕｃｙ２ｃ和ｃｄ３的抗原結合分子及其醫藥用途
CN116751303B (zh) * 2022-12-09 2023-12-26 华道(上海)生物医药有限公司 一种抗鸟苷酸环化酶2c的纳米抗体及其应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104395470A (zh) * 2012-04-27 2015-03-04 米伦纽姆医药公司 抗-gcc抗体分子和其用于测试对gcc标靶治疗的易感性的用途
US20160030595A1 (en) * 2012-04-26 2016-02-04 Thomas Jefferson University Anti-gcc antibody molecules and related compositions and methods
JP2018525033A (ja) * 2015-08-11 2018-09-06 レジェンド バイオテック アイルランド リミテッド 単一ドメイン抗体に基づくキメラ抗原受容体及びその使用方法
WO2019014891A1 (zh) * 2017-07-20 2019-01-24 深圳普瑞金生物药业有限公司 一种用于治疗肿瘤的egfr单域抗体cart及其应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009080764A2 (en) * 2007-12-20 2009-07-02 Abylnx N.V. Oral or nasal administration of compounds comprising amino acid sequences
BR112020013244A2 (pt) * 2018-01-04 2020-12-01 Shanghai Lumosa Therapeutics Co., Ltd. proteínas de fusão de anticorpo citosina-desaminase de domínio único
MX2020012607A (es) * 2018-05-23 2021-01-29 Pfizer Anticuerpos especificos para gucy2c y sus usos.
US11981920B2 (en) * 2018-12-04 2024-05-14 Innovative Cellular Therapeutics Holdings, Ltd. Modified cell with enhanced migration capability

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160030595A1 (en) * 2012-04-26 2016-02-04 Thomas Jefferson University Anti-gcc antibody molecules and related compositions and methods
CN104395470A (zh) * 2012-04-27 2015-03-04 米伦纽姆医药公司 抗-gcc抗体分子和其用于测试对gcc标靶治疗的易感性的用途
JP2018525033A (ja) * 2015-08-11 2018-09-06 レジェンド バイオテック アイルランド リミテッド 単一ドメイン抗体に基づくキメラ抗原受容体及びその使用方法
WO2019014891A1 (zh) * 2017-07-20 2019-01-24 深圳普瑞金生物药业有限公司 一种用于治疗肿瘤的egfr单域抗体cart及其应用

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CANCER IMMUNOL. RES., vol. 6, no. 5, JPN6025048929, 2018, pages 509 - 516, ISSN: 0005743919 *
LI, S. ET AL.: ""1304. Novel CoupledCARTMTechnology for Treating Colorectal Cancer", 2020 ASGCT Annual Meeting Abstr", MOLECULAR THERAPY, vol. Vol. 28, No. 4S1, JPN6025048932, 28 April 2020 (2020-04-28), pages 555, ISSN: 0005743920 *
ONCOIMMUNOLOGY, vol. Vol. 5, No. 10, e1227897, JPN6025048931, 2016, pages 1 - 10, ISSN: 0005743918 *

Also Published As

Publication number Publication date
EP4263615A4 (en) 2025-04-30
ECSP23053774A (es) 2023-09-29
EP4263615A1 (en) 2023-10-25
AU2021404641A1 (en) 2023-06-29
CL2023001665A1 (es) 2024-01-12
CO2023009279A2 (es) 2023-07-21
IL303610A (en) 2023-08-01
CN118146381A (zh) 2024-06-07
CA3205007A1 (en) 2022-06-23
CN116917329A (zh) 2023-10-20
WO2022127871A1 (en) 2022-06-23
AU2021404641A9 (en) 2024-09-19
CR20230245A (es) 2023-09-01
BR112023011658A2 (pt) 2023-10-17
MX2023006969A (es) 2023-08-25
KR20230131183A (ko) 2023-09-12
US20240059794A1 (en) 2024-02-22

Similar Documents

Publication Publication Date Title
WO2022012683A1 (en) Cd19 binding molecules and uses thereof
JP7747645B2 (ja) グリピカン－３（ｇｐｃ３）を標的化する抗体及びキメラ抗原受容体並びにその使用方法
CN115052901A (zh) 靶向bcma的单结构域抗体和嵌合抗原受体及其使用方法
US20260027209A1 (en) Claudin-6 binding moieties and uses thereof
WO2022012682A1 (en) Cd22 binding molecules and uses thereof
WO2022127871A1 (en) Gucy2c binding molecules and uses thereof
JP2023546765A (ja) Ｃｄ２０結合分子及びその使用
US20260091061A1 (en) Antibody and chimeric antigen receptors targeting gcc and methods of use thereof
WO2024041650A1 (en) Chimeric antigen receptors targeting interleukin 13 receptor subunit alpha 2 and methods of use thereof
EA049821B1 (ru) Связывающие gucy2c молекулы и их применение
HK40094778A (zh) Cd20结合分子及其用途
HK40079774A (en) Antibodies and chimeric antigen receptors targeting glypican-3 (gpc3) and methods of use thereof
HK40093439A (zh) Cd22结合分子及其用途
HK40075690A (en) Single domain antibodies and chimeric antigen receptors targeting bcma and methods of use thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230929

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241213

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20241213

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20251202

RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7422

Effective date: 20260205

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20260224

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20260205

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260302

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20260224

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20260224

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260413